Reimbursement

We support pharmaceutical, medical device and medical app companies in the development of pricing and reimbursement files for Belgium.

Services

Feasibility analysis on pricing and reimbursement of a product in Belgium
Tailor-made advice on the price and reimbursement strategy of a product
Development, submission and follow-up of price and reimbursement dossiers

Hict has extensive experience with health economics for Belgian reimbursement submissions.

Approx. 100 HEMAR projects, of which a majority of projects was to support reimbursement submissions
More than 90% of the submitted files have been reimbursed. We have also been applying health economics to support the broader market access challenges of our customers

Health Economic experience in many disease area's

Extensive number of reimbursement files in oncology and hematology: AML, aBCC , kidney cancer, melanoma, NSCLC, breast cancer, cervix & ovarian cancer, DLBCL, PaLL, HL, MCL, CLL/CML , HCC, soft tissue sarcoma
Other therapeutic areas: COPD, neurology (migraine, Parkinson), psychiatric (MDD, schizophrenia, alcohol dependence), uveitis, cardiology, HIV, dermatology, NAFL/NASH, etc.

The collaboration with Hict was extremely insightful as they built bridges between what the RIZIV wants to see in a reimbursement file and what we as a company want to realise for our patients.

NIELS VAN DRUTEN

GENERAL MANAGER - COCHLEAR BENELUX

Inspiring cases

07 august 2019

Patient blood management in Belgium

06 august 2019

A health economic analysis of a new drug for treatment of symptomatic leiomyoma in Belgium

16 september 2019

Cochlear: Budget impact criteria reimbursement implants

Interested in our expertise on Reimbursement?

Get in touch